Interv Akut Kardiol. 2019;18(1):43-44
PCSK9 and the ODYSSEY trial
- 1 Interní kardiologická klinika, LF MU a FN Brno, ICRC Brno
- 2 Interní kardioangiologická klinika, LF MU a FN u sv. Anny, Brno
In the year 2018, the ODYSSEY OUTCOMES trial was presented that completed a long-term programme with alirocumab. The ODYSSEY programme consists of 9 clinical trials, of which a pooled analysis was performed. The aim of this analysis was to evaluate the data on the efficacy and safety of alirocumab in patients who had DM and concomitant atherosclerotic CV disease. The Odyssey Outcomes trial included 18,924 patients in secondary prevention who had experienced an acute coronary syndrome within the previous 12 months; the mean follow-up duration was 2.8 years and the primary endpoint occurred in 1,955 of them. The primary endpoint occurred in 903 (9.5 %) patients in the active treatment group and in 1,052 (11.1 %) in the placebo group (p = 0.0003). No typical adverse effects were reported, except for puncture site reaction. The greatest benefit was seen in patients with LDL cholesterol above 2.6 mmol/l, where alirocumab reduced the composite endpoint by 24 % and all-cause mortality by 29 %.
Keywords: alirocumab, cholesterol, Odyssey, mortality
Published: March 8, 2019 Show citation
